ArticleCureus2025
Current Practices in, Reimbursement Opinions About, and Clinical Indications of Adaptive Radiation Therapy: Results From the American College of Radiation Oncology Survey.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdaptive radiation therapy (ART) is generally defined as adjusting radiation dose delivery based on changes observed in the tumor or surrounding normal tissues during the course of treatment. Improvements in dosimetry with ART have been widely reported in the literature, in addition to the increased costs attributed to increased physician time and capital investment. ART utilization has been steadily rising, now with multiple available treatment platforms, but there is no generally accepted guideline for proper billing and reimbursement. No specific billing code for ART is currently available. Considering the heterogeneity of billing practices and limited published data on utilization trends, the American College of Radiation Oncology (ACRO) Government Relations and Economics Committee developed a survey to understand current clinical and billing practices while gauging the opinions of the community about appropriate reimbursement.
methodsA two-part 21-item questionnaire was developed by ACRO and distributed amongst its members who are practicing attendings. The first section was intended for all attendings, including non-users of ART, and focused on opinions surrounding reimbursement, while the second section was meant only for ART-users, focusing on current billing practices and clinical utilization. Responses were collected between January 27, 2025 and April 1, 2025 and responses are reported with frequency counts and percentages.
resultsA total of 123 responses were collected, 51 were ART-users. A majority of respondents felt that a new billing code for ART should be developed (n=106; 87.8%) and a majority of respondents (n=101; 82.1%) either agreed or strongly agreed with the statement "Adaptive RT treatments should be reimbursed more than standard RT treatments." Users are treating the full spectrum of disease with ART and using it for standard fractionation, hypofractionation and Stereotactic Body Radiation Therapy (SBRT). Attending physicians were almost universally involved in daily contouring for target volumes (n=46; 93.9%). Most users felt that their ART cases are generally more complex compared to non-ART cases (n=41; 83.7%) and proceeded with adaptation due to either changes in tumor volume (n=44; 89.8%) or changes in organs-at-risk (OARs) (n=40; 81.6%). Billing practices varied among ART-users and many respondents were unaware of which billing codes were being utilized (n=29; 59.2%).
conclusionThis survey represents the first published material on the current clinical landscape and reimbursement practices of ART. ART is being used in many different ways and while current billing and clinical practices vary, the general opinion within the radiation oncology community is that ART should be reimbursed more than standard radiation treatments and we could benefit from the development of a unique billing code.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.